BioVie Inc is preparing to advance its Phase 3 clinical trial for bezisterim, a drug targeting Parkinson’s disease, following promising Phase 2 results. The company has requested an End-of-Phase 2 meeting with the FDA to finalize the Phase 3 trial design, focusing on motor symptoms as the primary endpoint and non-motor symptoms as a co-primary or secondary endpoint. Phase 2 data showed potential benefits especially in patients with higher inflammation levels. BioVie aims to discuss trial details with the FDA later this fall and expects formal feedback by the end of 2026. The drug is also being tested for Long COVID and Alzheimer’s disease.
Roivant Sciences saw its price target raised to $52 by Jefferies, reflecting a 24.7% potential gain, following positive Phase 2 trial results for mosliciguat, a drug treating pulmonary hypertension linked to interstitial lung disease. The trial showe...
EVI Industries reported Q4 revenue of $121.87 million, surpassing analyst expectations of $117.1 million, and achieved a record fiscal year revenue of $446.6 million, marking a 15% increase year-over-year. The company met earnings per share forecasts...
Lakeland Industries continues to face profitability challenges with a projected negative EPS of -$0.06 and recent unprofitability. However, the company secured important contracts with the Hong Kong Government Flying Service and Airports of Thailand,...
Intel's stock surged after Northland Securities upgraded it from "Market Perform" to "Outperform" with a $120 price target, following Intel Foundry's progress in High Numerical Aperture Extreme Ultraviolet (High-NA EUV) lithography. Intel has process...
ABM Industries reported strong Q3 2026 results, surpassing analyst EPS estimates with $1.04 per share versus the expected $1.01. The company achieved record revenue of $2.3 billion, a 4.2% increase driven by organic and acquisition growth. Adjusted n...
